TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00482313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR OROS Methylphenidate
Description: PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study: NCT03179618

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.

Intervention type: DRUG
Group type: OTHER
Intervention: Lipid Regulating Drugs
Description: Mainly including statins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Regulating Drugs
Description: Mainly including statins

Intervention type: DRUG
Group type: OTHER
Intervention: Coronary Vasodilator
Description: Mainly including nitrates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coronary Vasodilator
Description: Mainly including nitrates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Decoction
Description: Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
Study: NCT03189797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tailored preventive program
Description: In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions.
Study: NCT00794261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of Pegfilgrastim
Description: Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection of Filgrastim
Description: Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN \> 0.5 G/L)
Study: NCT04434313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delivery of iStride™ device gait treatment using telemedicine
Description: The gait device used in this study mimics the actions of the split-belt treadmill but can be used during overground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking. This research aims to adapt the delivery mechanism of treatment with the iStride™ device to include telemedicine. The telemedicine platform of reference in this study, the Moterum Digital Platform, is an integrated therapeutic platform which offers an activity library, real-time video conferencing, and outcomes tracking. Our primary study objective is to determine if telemedicine is a safe and feasible delivery method for treatment with the iStride ™ gait device.
Study: NCT00132509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFIL
Description: Alteplase : 0.8mg/kg over 90 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NINDS
Description: Alteplase : 0.9mg/kg over 60 minutes
Study: NCT00171509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine microemulsion
Study: NCT05198024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition knowledge
Description: Nutrition knowledge either 'Usual care plus new education programme' or 'Usual care plus biggest loser'
Study: NCT04637984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREP2 algorithm
Description: A) PREP2. It combines clinical measures and neurological biomarkers in the initial days after stroke: 1) SAFE score (day 3), which is the sum of shoulder abduction and finger extension strength in the paretic upper limb using the Medical Research Council (MRC); 2) NIH Stroke Scale (day 3); 3) transcranial magnetic stimulation (day 3-7) to determine the presence of MEPs in the paretic arm. According with the aforementioned measures, 4 categories of upper limb recovery will be identified: EXCELLENT, GOOD, LIMITED and POOR.
Study: NCT02892110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 2 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mg daily
Study: NCT00249106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADVAX

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ADVAX
Study: NCT03360708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00171509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion
Study: NCT03360708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
Description: Given ID
Study: NCT03465410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosage of Tacrolimus
Description: Immediate release Tacrolimus (Prograf/Adoport)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bayesian Prediction Tacrolimus dosage
Description: Immediate release Tacrolimus (Prograf/Adoport)
Study: NCT02570126

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix HSA-free
Description: 2 doses will be administered, one at Day 0 and the other at Day 42

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varilrix™
Description: 2 doses will be administered, one at Day 0 and the other at Day 42
Study: NCT03351972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klean Prep
Description: Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klean Prep
Description: Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clear liquids only
Description: Participants randomised to clear liquids only will receive guidance to only drink clear liquids before their procedure
Study: NCT02045394

Intervention type: OTHER
Intervention: Chest X-ray
Study: NCT04357522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15-Valent Pneumococcal Conjugate Vaccine
Description: 4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-Valent Pneumococcal Conjugate Vaccine
Description: 4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
Study: NCT00764010

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No dietary counseling and omega-3 capsules
Description: Omega-3 2.4 g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 capsules and dietary counseling
Description: Omega-3 2.4 g/day and Mediterranean-like diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling, placebo capsules for omega-3
Description: Mediterranean-like diet
Study: NCT03565159

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: Pneumococcal polysaccharide conjugate vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Placebo
Study: NCT01387516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Intervention
Description: The MI session will be 60-90 minutes in length.The focus is on establishing rapport and building motivation. The counselor explores teen's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancies, and perceptions of self-efficacy.A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Description: The Relaxation Therapy intervention encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and meditation to reduce stress; which may lead to substance use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The Cognitive-Behavioral Therapy (CBT) Intervention focuses on the interrelationship between thoughts, feelings, and behaviors. It addresses specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Programming
Description: The Self-Help Programming intervention combines elements of Nicotine anonymous (NicA) to provide someone who uses nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. It incorporate the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine.
Study: NCT02954029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ezClot (hemostasis pad)
Description: ezClot pad uses chitosan, a deacetylated complex carbohydrate derived from the naturally occurring substance chitin, to accelerate blood clotting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ezClot (hemostasis pad)
Description: ezClot pad uses chitosan, a deacetylated complex carbohydrate derived from the naturally occurring substance chitin, to accelerate blood clotting.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BloodSTOP ix pad
Description: BloodSTOP® pad is an etherized and oxidized regenerated cellulose matrix that achieves hemostasis by activating the intrinsic coagulation pathway.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotary compression device
Description: Rotary compression device consists of a plastic arch and a rotary screw to deliver local pressure by moving the silicone compression pad.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotary compression device
Description: Rotary compression device consists of a plastic arch and a rotary screw to deliver local pressure by moving the silicone compression pad.
Study: NCT00003140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02999269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECTA Spectrum 5000Q Amplitude
Description: Current

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECTA Spectrum 5000Q Amplitude
Description: Current

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MECTA Spectrum 5000Q Amplitude
Description: Current
Study: NCT04607694

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Description: Proton radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon radiotherapy
Description: Photon radiotherapy
Study: NCT02045394

Intervention type: OTHER
Intervention: computed tomography of the chest

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: In patients with haemoptysis bronchoscopy will be performed with flexible bronchoscope. A systemic research of bleeding site and causes will be done. Microbiological or pathological sampling will be executed if clinically required. In selected patients, bronchoscopy might be performed with the rigid instrument or the flexible bronchoscope in intubated patients.
Study: NCT01379872

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: This is a non-interventional study

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: This is a non-interventional study

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: This is a non-interventional study
Study: NCT02610738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Junior KICk-OFF education programme
Description: The Junior KICk-OFF course is an age appropriate eduction course which aims to improve the understanding and knowledge of children with type 1 diabetes. It has been designed with school teachers and educationalists to meet the learning needs of children aged 4-11yrs
Study: NCT03128996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIC regimen
Description: Days -60 to -21: hydroxyurea (30mg/kg/day po) \>6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if \< 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if \< 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD prophylaxis regimen
Description: Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus \& Start of mycophenolate mofetil (MMF) Days +5, +14, +30, +60, +90: abatacept (IND) (10mg/kg/day IV) Days +120 to +390: abatacept (IND) monthly (5mg/kg/day IV)
Study: NCT00569582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
Study: NCT00487617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fruit juice or placebo absorption
Description: absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fruit juice or placebo absorption
Description: absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
Study: NCT03113643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-401
Description: SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-401
Description: SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.
Study: NCT04367584

Intervention type: OTHER
Intervention: Clinical and laboratory examination
Description: Clinical and laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)

Intervention type: OTHER
Intervention: Clinical and laboratory examination
Description: Clinical and laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
Study: NCT03628287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revised Care Coordination Program
Description: Greater focusing, tailoring and cues for delivery of key components of Care Coordination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Original Care Coordination Program
Description: Original Care Coordination
Study: NCT01275313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lightweight wheelchair
Description: Seating and wheeled mobility assessment and fitting of a lightweight wheelchair

Intervention type: DEVICE
Group type: OTHER
Intervention: Skin Protection Cushion
Description: Seating assessment and provision of a cushion meeting CMS code for Skin Protection wheelchair cushion
Study: NCT04085328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LID015385 soft contact lenses
Description: Investigational silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A soft contact lenses
Description: Silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
Study: NCT01371513

Intervention type: OTHER
Intervention: continuous screening
Description: practice patterns for screening prostate cancer
Study: NCT03362151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular pasta
Description: Regular pasta (Approximately 42 grams carbohydrate per meal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein pasta
Description: High protein pasta (Approximately 38 grams carbohydrate per meal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White rice
Description: White rice (Approximately 43 grams carbohydrate per meal)
Study: NCT04447274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Apatinib
Description: Subject will receive SHR-1210 200mg every 2 weeks, with intravenous drip Apatinib 425 mg, oral, 5 consecutive days, 2 days off,each 14 day of a cycles
Study: NCT01801696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent massage tx group
Description: The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
Study: NCT03664869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG instillation therapy
Description: Induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential BCG and EMDA mitomycin C
Description: Induction period includes nine weekly instillations of sequential BCG and EMDA-MMC instillations applied as three cycles of BCG, BCG and EMDA-MMC. Induction period is followed by maintenance period of nine monthly instillations of sequential EMDA-MMC and BCG applied with three cycles of EMDA-MMC, EMDA-MMC and BCG.~BCG instillation is performed as a standard instillation.~Mitomycin C is administered with electromotive drug administration (EMDA) device (Instillation: 40 mg mitomycin C with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water, EMDA settings: current rise rate 30-50 microamperes per second, max 25 milliamperes, treatment duration 30 min)
Study: NCT03018405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 cells
Description: In cohorts 1-6, the schedule of administration will be 3 NKR-2 doses administered with a 2-week interval. In absence of progressive disease at the first tumor assessment following NKR-2 administration (on Visit D29 for hematological tumors or on Visit D57 for solid tumors), and according to product availability, the patient will receive a new cycle of 3 administrations maximum with a 2-week interval, at a dose of 1x109 NKR-2 cells per injection, or at the same dose of cycle 1 if it was below 1x109 NKR-2 cells.~Patients in cohorts 8-9 (solid arm) and 10-11 (hematological arm) of first segment will receive 3 treatment doses at 1x109 NKR-2 (cohorts 8 and 10) or 3x109 NKR-2 (cohorts 9 and 11) per injection, with a 1-week interval between each dose. A second cycle of three NKR-2 injections at the same dose as in 1st cycle will be administered 2 weeks after the third NKR-2 injection, and with a 2-week interval between each dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 cells
Description: In cohorts 1-6, the schedule of administration will be 3 NKR-2 doses administered with a 2-week interval. In absence of progressive disease at the first tumor assessment following NKR-2 administration (on Visit D29 for hematological tumors or on Visit D57 for solid tumors), and according to product availability, the patient will receive a new cycle of 3 administrations maximum with a 2-week interval, at a dose of 1x109 NKR-2 cells per injection, or at the same dose of cycle 1 if it was below 1x109 NKR-2 cells.~Patients in cohorts 8-9 (solid arm) and 10-11 (hematological arm) of first segment will receive 3 treatment doses at 1x109 NKR-2 (cohorts 8 and 10) or 3x109 NKR-2 (cohorts 9 and 11) per injection, with a 1-week interval between each dose. A second cycle of three NKR-2 injections at the same dose as in 1st cycle will be administered 2 weeks after the third NKR-2 injection, and with a 2-week interval between each dose.
Study: NCT04508439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.
Study: NCT01801696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent massage wait-list control group
Description: The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.